Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics : Management Change/Compensation (Form 8-K)

06/07/2021 | 06:33am EDT

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 4, 2021, Andrew Saik tendered his resignation from his role as Treasurer and Chief Financial Officer of VYNE Therapeutics Inc. ('VYNE' or the 'Company') to pursue another opportunity, effective as of June 18, 2021. Mr. Saik's decision to resign is not related to any disagreement with the Company. Mr. Saik joined VYNE in March 2020 following the transaction which combined the businesses of Foamix Pharmaceuticals Ltd. ('Foamix') and Menlo Therapeutics Inc. We would like to thank Andrew for his contributions to VYNE as we integrated Menlo and Foamix into a combined company and pivoted to becoming a fully integrated commercial company incorporated in Delaware. We wish him continued success in his future endeavors.

On behalf of the Board of Directors, the Company has named Tyler Zeronda, 35, who is currently Vice President of Finance of the Company, to serve as interim Chief Financial Officer and Treasurer of VYNE effective as of June 18, 2021 until a permanent replacement is named. In this role Mr. Zeronda will serve as the Company's Principal Financial Officer and Principal Accounting Officer. Mr. Zeronda joined Foamix in April 2019 and has been responsible for all finance activities related to the commercial operations, financial planning, treasury, risk management and supply chain matters of the Company. From April 2013 until April 2019, Mr. Zeronda held positions of increasing responsibility in finance at Aerie Pharmaceuticals Inc. ('Aerie'), a Nasdaq listed company, culminating in his role as Director of Finance. While at Aerie, Mr. Zeronda helped lead his department's transition from that of a development-stage entity to a fully integrated commercial finance organization supporting the launch of multiple drugs. Prior to joining Aerie, Mr. Zeronda was employed at Ernst & Young, LLP where he focused on assurance services in the healthcare industry. Mr. Zeronda received his Master of Science in accounting from the University of Virginia, holds a Bachelor of Arts in economics and business from Lafayette College and is a licensed CPA.

In connection with the employment of Mr. Zeronda as Interim Chief Financial Officer and Treasurer of the Company, Mr. Zeronda and the Company entered into an Offer Letter on June 7, 2021 (the 'Offer Letter'). Pursuant to the Offer Letter, Mr. Zeronda will receive an annual base salary equal to $300,000 and an annual bonus opportunity of up to 35% of base salary.

The Offer Letter provides that, in the event of a termination of his employment as interim Chief Financial Officer and Treasurer without Cause (as defined in the Company 2019 Equity Incentive Plan), subject to his execution of a release of claims, Mr. Zeronda will receive (i) a lump sum severance payment equal to 75% of his base salary then in effect and (ii) continued healthcare plan coverage at active employee rates for nine (9) months following the date of termination, provided that the Company's obligation under clause (ii) shall terminate on the earlier of (x) the date on which he enrolls in a group health plan offered by another employer and (y) the date on which he is no longer eligible for continuation coverage under COBRA.

In addition, if Mr. Zeronda's employment as interim Chief Financial Officer and Treasurer is terminated by the Company without Cause or he terminates his employment with Good Reason (as defined in the Offer Letter) within the twelve month period after a Change of Control (as defined in the 2019 Equity Incentive Plan), he will be entitled to receive a change of control payment equal to (i) one times (1.0x) the sum of his then current base salary plus his target bonus, (ii) his pro rata target bonus for the year of termination, and (iii) continued healthcare plan coverage at active employee rates for twelve (12) months following the date of termination, provided that the Company's obligation under clause (iii) shall terminate on the earlier of (x) the date on which he enrolls in a group health plan offered by another employer and (y) the date on which he is no longer eligible for continuation coverage under COBRA. In addition, in the event of such a termination, all of Mr. Zeronda's unvested stock options and restricted stock units will become fully vested.

The Offer Letter also provides for customary confidentiality, non-competition and non-solicitation covenants.

There are no arrangements or understandings between Mr. Zeronda and any other persons pursuant to which he was selected as interim Chief Financial Officer. There are also no family relationships between Mr. Zeronda and any director or executive officer of the Company and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The foregoing description of the Offer Letter does not purport to be complete and is qualified in its entirety by reference to the Offer Letter, which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2021.

Disclaimer

Vyne Therapeutics Inc. published this content on 07 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 June 2021 10:32:05 UTC.


ę Publicnow 2021
All news about VYNE THERAPEUTICS INC.
07/19VYNE THERAPEUTICS : Certificate of Amendment to the Amended and Restated Certifi..
PU
07/19VYNE THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fis..
AQ
07/19VYNE THERAPEUTICS : Says Austin Institute for Clinical Research Launches Study o..
MT
07/19VYNE THERAPEUTICS : Announces Initiation of Investigator Initiated Trial Evaluat..
AQ
07/19VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evalua..
CI
07/02VYNE THERAPEUTICS INC. : Other Events (form 8-K)
AQ
07/02Vyne Therapeutics Receives A Paragraph IV Certification Notice from Perrigo I..
CI
06/29VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Develo..
GL
06/25VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell Microcap Value Inde..
CI
06/25VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell 3000 Value Index
CI
More news
Financials (USD)
Sales 2021 34,0 M - -
Net income 2021 -73,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,98x
Yield 2021 -
Capitalization 139 M 139 M -
Capi. / Sales 2021 4,08x
Capi. / Sales 2022 1,77x
Nbr of Employees 106
Free-Float 86,6%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 2,70 $
Average target price 11,43 $
Spread / Average Target 323%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-57.28%192
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308